Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Discovery Grants Program - Individual

University of Alberta

$46,000.00

Structural and regulatory mechanistic study of angiotensin converting enzyme 2 (ACE2) upregulating peptide IRW

FY 2024-25

Summary
In addition to providing essential amino acids and energy, food proteins are sources of bioactive peptides. Bioactive peptides are small fragments of proteins that may have vast potential for improving human health and preventing chronic diseases. These peptides are inactive within the proteins but can be released by hydrolysis via fermentation or protease. My previous research progresses through Discovery Grants have significantly advanced our understanding about the potential of food proteins as a source of bioactive peptides, in particular antihypertensive peptides, and their structure and activity relationships. Most antihypertensive peptides are characterized as inhibitors of angiotensin converting enzyme (ACE), a key enzyme responsible for the generation of a peptide called angiotensin II (Ang II); Ang II is a vasoconstrictor, and thus, elevated Ang II level causes vasoconstriction, oxidative stress, and inflammation, leading to high blood pressure. Our previous study has identified a tripeptide IRW (isoleucine-arginine-tryptophan) from egg white initially as an ACE inhibitor. Interestingly, animal study revealed that its blood pressure lowering activity is due to upregulation of angiotensin converting enzyme 2 (ACE2), but not ACE inhibition. ACE2 is a homologue of ACE, but with opposite physiological effects as ACE2 can degrade Ang II to generate another peptide, Ang (1-7), a vasodilator. The application aims to understand how ACE2 is regulated by the peptide IRW. Like many peptides, peptide IRW is susceptible to degradation during digestion and absorption, despite its ability to lower high blood pressure in animals. Thus, we hypothesize that tripeptide IRW's metabolites, but not the intact tripeptide, are responsible for the upregulation of ACE2 via transcription factors. First, the bioavailability and pharmacokinetics of IRW will be studied. Next, the essential structural requirements of peptide IRW for its ACE2 upregulating activity will be determined. The potential transcription factors and metabolites will be identified respectively via transcriptome and metabolome analyses, and the regulatory roles of the transcription factors and metabolites will be first validated in cells and then in animals. Understanding the bioavailability and pharmacokinetics of peptide IRW, along with the identification of the essential structural requirements and the underlying mechanisms of ACE2 regulation, will shed light on the molecular mechanisms of action of food-derived peptides. Understanding the underlying mechanisms of action will facilitate the translational research towards the development of peptide IRW as a dietary strategy to prevent and/or mitigate cardiovascular diseases-the leading cause of death in Canada and in the world.
Program
Discovery Grants Program - Individual
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
RGPIN-2024-06084
Name nom
Wu, Jianping
Department département
Agricultural, Food and Nutritional Sciences
Organization id
9
Institution établissement
University of Alberta
Province en
Alberta
Province fr
Alberta
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2024
Competition year année de concours
2024
Award amount
46000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
DISCOVERY RESEARCH
Group fr
RECHERCHE AXÉE SUR LA DÉCOUVERTE
Committee code
1502
Committee name en
Biological Systems and Functions
Committee name fr
Systèmes et fonctions biologiques
Area of application code
501
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Processed food products and beverages
Area of application fr
Aliments transformés et boissons
Research subject code
6100
Research subject group en
Food science and technology
Research subject group fr
Science et technologie de l'alimentation
Research subject en
Food science and technology
Research subject fr
Science et technologie de l'alimentation
Field of research list names en
Not available
Field of research list names fr
Non disponible
Socioeconomic objective list names en
Not available
Socioeconomic objective list names fr
Non disponible
Application title
Structural and regulatory mechanistic study of angiotensin converting enzyme 2 (ACE2) upregulating peptide IRW
Keywords
angiotensin converting enzyme 2 (ace2); bioactive peptides; peptide isoleucine-arginine-tryptophan (irw); spontaneously hypertensive rats (shr); bioavailability; structural requirements; bioinformatics; metabolome; regulatory mechanism; cell culture
Application summary
In addition to providing essential amino acids and energy, food proteins are sources of bioactive peptides. Bioactive peptides are small fragments of proteins that may have vast potential for improving human health and preventing chronic diseases. These peptides are inactive within the proteins but can be released by hydrolysis via fermentation or protease. My previous research progresses through Discovery Grants have significantly advanced our understanding about the potential of food proteins as a source of bioactive peptides, in particular antihypertensive peptides, and their structure and activity relationships. Most antihypertensive peptides are characterized as inhibitors of angiotensin converting enzyme (ACE), a key enzyme responsible for the generation of a peptide called angiotensin II (Ang II); Ang II is a vasoconstrictor, and thus, elevated Ang II level causes vasoconstriction, oxidative stress, and inflammation, leading to high blood pressure. Our previous study has identified a tripeptide IRW (isoleucine-arginine-tryptophan) from egg white initially as an ACE inhibitor. Interestingly, animal study revealed that its blood pressure lowering activity is due to upregulation of angiotensin converting enzyme 2 (ACE2), but not ACE inhibition. ACE2 is a homologue of ACE, but with opposite physiological effects as ACE2 can degrade Ang II to generate another peptide, Ang (1-7), a vasodilator. The application aims to understand how ACE2 is regulated by the peptide IRW. Like many peptides, peptide IRW is susceptible to degradation during digestion and absorption, despite its ability to lower high blood pressure in animals. Thus, we hypothesize that tripeptide IRW's metabolites, but not the intact tripeptide, are responsible for the upregulation of ACE2 via transcription factors. First, the bioavailability and pharmacokinetics of IRW will be studied. Next, the essential structural requirements of peptide IRW for its ACE2 upregulating activity will be determined. The potential transcription factors and metabolites will be identified respectively via transcriptome and metabolome analyses, and the regulatory roles of the transcription factors and metabolites will be first validated in cells and then in animals. Understanding the bioavailability and pharmacokinetics of peptide IRW, along with the identification of the essential structural requirements and the underlying mechanisms of ACE2 regulation, will shed light on the molecular mechanisms of action of food-derived peptides. Understanding the underlying mechanisms of action will facilitate the translational research towards the development of peptide IRW as a dietary strategy to prevent and/or mitigate cardiovascular diseases-the leading cause of death in Canada and in the world.